Under the terms of the agreement, Forest will make an upfront payment of $240 million and additional payments to Merck based on defined sales milestones. Merck will remain responsible for product supply. Forest will assume responsibility for continued commercialization, including completing certain post marketing studies of Saphris following a transition period.
GN 440.6 Stainless Steel Leveling Feet are now offered with Fixing Lug with Tapped Socket, With Plastic Base Cap or Rubber Pad, in inch and metric sizes. These RoHS-complaint leveling feet are simple, economically priced components.
The Traceable® Infrared Thermometer Gun takes instant, less-than-a-second, temperature readings of any surface. The design permits one-handed point-and-shoot results. Laser-sighting beam permits aiming precisely at targeted surface.
Takeda Pharmaceutical has announced that Christophe Weber has been approved at the company's Board of Directors Meeting to become Chief Operating Officer (COO) and candidate as the next Chief Executive Officer (CEO). Mr. Weber will join Takeda to take the role of COO by April 2014.
GE Healthcare Life Sciences, and JHL Biotech today announced that GE Healthcare has completed installation of its FlexFactory™ biomanufacturing platform at JHL Biotech’s Research Center and manufacturing plant in Hsinchu, Taiwan. The new manufacturing platform will follow current good manufacturing practices (cGMP) and be fully operational by the end of 2013.
A traveling medical technician who infected dozens of patients in multiple states with hepatitis C through tainted syringes is due to find out today how many decades he'll spend in a New Hampshire prison. Kwiatkowski, who has admitted stealing painkillers and replacing them with saline-filled syringes tainted with his blood, pleaded guilty in August to 16 federal drug charges.
Canadian scientists believe they have found the "Achilles heel" of colon cancer stem cells, which appear to be responsible for the recurrence of the disease in many patients who have gone into remission after treatment. Researchers at Toronto's University Health Network have used an experimental drug to disable a gene that regulates these stem cells, which are thought to initiate the development of colon cancer.
A class action suit by Australian and New Zealand victims of Thalidomide against the anti-morning sickness drug's British distributor Diageo Scotland Ltd. has been settled for 89 million Australian dollars ($81 million), a lawyer said on Monday.
Timothy C. Tyson, Chairman of Aptuit LLC, announced today the appointment of Jonathan Goldman, MD as Chief Executive Officer (CEO), completing the company's senior management leadership team. Dr. Goldman will focus his efforts on the growth of Aptuit as a leading provider of outsourced services in the early development space by establishing new partnerships with clients and pursuing strategic acquisitions.
Biogen Idec announced today that the U.S. Food and Drug Administration (FDA) has extended the initial Prescription Drug User Fee Act (PDUFA) date for its review of the Biologics License Application (BLA) for ALPROLIX™, the company’s investigational long-lasting recombinant factor IX Fc fusion protein candidate for hemophilia B.
AcelRx Pharmaceuticals, Inc. has announced that the Zalviso New Drug Application (NDA) was accepted for filing by the FDA on November 26, 2013. The acceptance for filing of the NDA indicates the FDA has determined that the application is sufficiently complete to permit a substantive review.
Tour attendees will gain insight into the latest innovations and learn about new technologies offered by vendors and internationally recognized experts that provide a platform to support manufacturing excellence, including efficiency, flexibility and reduction of overall costs.
The Supreme Court agreed Tuesday to referee another dispute over President Barack Obama's health care law, whether businesses can use religious objections to escape a requirement to cover birth control for employees.
Specialty drugmaker BTG PLC has received U.S. approval to market an injectable drug to treat patients with varicose veins. The drug, Varithena, is pharmaceutical foam dispensed from a canister device.